Launch of Phase 3 clinical trial with Nefecon in Japan
Rhea-AI Summary
Calliditas Therapeutics (NASDAQ: CALT) has announced that its partner, Viatris Pharmaceutical Japan, initiated a Phase 3 clinical trial in Japan with Nefecon, branded as VR-205. This trial focuses on Japanese patients with IgA nephropathy (IgAN), a condition affecting an estimated 33,000 people in Japan. The trial is a bridging study, similar to the global NefIgArd trial, requiring a number of participants. This initiative follows a license agreement enabling Viatris to register and commercialize Nefecon in Japan, addressing the treatment options available for IgAN patients.
Positive
- Initiation of Phase 3 clinical trial with Nefecon in Japan.
- The trial will address the needs of approximately 33,000 IgAN patients in Japan.
- License agreement with Viatris for the registration and commercialization of Nefecon in Japan.
Negative
- None.
News Market Reaction – CALT
In the trading session that priced this news, CALT declined 0.10%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in
*
CONTACT:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on July 4, 2024 at 08:30 a.m. CET.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Viatris Trial Launch PR_ENG |
View original content:https://www.prnewswire.com/news-releases/launch-of-phase-3-clinical-trial-with-nefecon-in-japan-302189467.html
SOURCE Calliditas Therapeutics